Q2 2026 13F · SEC CIK 1663865
Orbis Allan Gray Ltd
Investment managerFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $29.1B
- Reported positions
- 97
- Top holdings a year, 3 yrs
- +13.2%
- Average holding period
- 3.0 yrs
Orbis Allan Gray Ltd is an investment manager that reported 97 positions worth $29.1B in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Corpay Inc (CPAY, 6.2%), Nebius Group N.v. (NBIS, 6.2%), Booking Holdings Inc (BKNG, 4.4%). A portfolio copying its top holdings returned 13.2% a year over the last 3 years, against 22.3% for the S&P 500.
Orbis Allan Gray Ltd holdings largest 50 of 97 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
What Orbis Allan Gray Ltd bought and sold in Q2 2026, against Q1 2026.
New positions
Q1 2026's filing was too long to tell new positions apart.
Added to
- BKNG Booking Holdings Inc+9648.4% shares
- INSM Insmed Inc+224.5% shares
- PDD Pdd Holdings Inc+207.0% shares
- RRC Range Res Corp+147.3% shares
- SHEL Shell PLC+115.1% shares
- ALNY Alnylam Pharmaceuticals Inc+48.9% shares
- SRRK Scholar Rock Hldg Corp+42.0% shares
- RHI Robert Half Inc.+30.9% shares
Reduced
- SW Smurfit Westrock PLC F-57.3% shares
- PRAX Praxis Precision Medicines I-38.1% shares
- VALE Vale S A-26.3% shares
- CX Cemex Sab de Cv Spon ADR New-23.8% shares
- NBIS Nebius Group N.v.-21.9% shares
- RNR Renaissancere Holdings-16.4% shares
- GMAB Genmab A/s-12.0% shares
- CRSP Crispr Therapeutics AG-10.8% shares
Left the top 50
- WLK Westlake Corpwas 2.6%
- AES AES Corpwas 0.7%
- SE Sea Ltdwas 0.6%
- California Res Corpwas 0.6%
- R Ryder Sys Incwas 0.6%
- EAT Brinker Internationalwas 0.6%
- DYN Dyne Therapeutics Incwas 0.5%
Share counts compared with the Q1 2026 13F; a split also changes share counts. The latest filing lists more than 50 positions, so a position that left the top 50 may still be held.
How the holdings did against the S&P 500.
- 1 year
- -0.2% /yr
- S&P 500 +11.7%
- 3 years
- +13.2% /yr
- S&P 500 +22.3%
- 5 years
- +6.6% /yr
- S&P 500 +10.6%
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $29.1B | 97 |
| Q1 2026 | $23.7B | 91 |
| Q4 2025 | $23.9B | 89 |
| Q3 2025 | $23.3B | 86 |
| Q2 2025 | $20.6B | 78 |
| Q1 2025 | $17.5B | 78 |
| Q4 2024 | $18.6B | 84 |
| Q3 2024 | $18.9B | 80 |
| Q2 2024 | $16.1B | 76 |
| Q1 2024 | $16.7B | 71 |
| Q4 2023 | $15.9B | 73 |
| Q3 2023 | $13.9B | 76 |
Questions about Orbis Allan Gray Ltd's portfolio
What stocks does Orbis Allan Gray Ltd own?
Orbis Allan Gray Ltd's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 97 positions worth $29.1B. The largest are Corpay Inc (CPAY) at 6.2%, Nebius Group N.v. (NBIS) at 6.2%, Booking Holdings Inc (BKNG) at 4.4%, Qxo Inc (QXO) at 4.4% and Bruker Corp (BRKR) at 3.7%.
What did Orbis Allan Gray Ltd buy last quarter?
In Q2 2026, Orbis Allan Gray Ltd added Booking Holdings Inc (BKNG) (+9648.4% shares), Insmed Inc (INSM) (+224.5% shares) and Pdd Holdings Inc (PDD) (+207.0% shares), compared with its Q1 2026 filing.
What did Orbis Allan Gray Ltd sell last quarter?
In Q2 2026, Orbis Allan Gray Ltd cut from its top 50 Westlake Corp (WLK), cut from its top 50 AES Corp (AES), cut from its top 50 Sea Ltd (SE), cut from its top 50 California Res Corp, cut from its top 50 Ryder Sys Inc (R), Smurfit Westrock PLC F (SW) (-57.3% shares), Praxis Precision Medicines I (PRAX) (-38.1% shares) and Vale S A (VALE) (-26.3% shares), compared with its Q1 2026 filing.
How has Orbis Allan Gray Ltd's portfolio performed?
A portfolio copying Orbis Allan Gray Ltd's 20 largest 13F holdings each quarter, from the day each filing was public, returned +13.2% a year over the last 3 years, against +22.3% for the S&P 500. Over 1 year: -0.2% against +11.7%. Over 5 years: +6.6% a year against +10.6%.
When is Orbis Allan Gray Ltd's next 13F filing due?
13F filings are due 45 days after each quarter ends. Orbis Allan Gray Ltd's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.